ver-EN-i-cline

Therapeutic Classification:

Pharmacologic Classification: nicotine.agonists

• Treatment of smoking cessation; in conjunction with nonpharmacologic support (educational materials/counseling).

• Selectively binds to alpha₄, beta₂ nicotinic acetylcholine receptors, acting as a nicotine agonist; prevents the binding of nicotine to receptors.

• Decreased desire to smoke.

Absorption: 100% absorbed following oral administration.

Distribution: 24 hr.

Metabolism/Excretion: Minimally metabolized; 92% excreted in urine unchanged.

Half-life: 24 hr.

Contraindicated in:

• Hypersensitivity
• Lactation: Lactation.

Use Cautiously in:

• Severe renal impairment (↓ dose recommended if CCr <30 mL/min)
• Stable cardiovascular disease (may ↑ risk of cardiovascular events)
• Psychiatric illness
• Seizure disorders
• OB: Use during pregnancy only if potential maternal benefit outweighs potential fetal risk
• Pedi: Safety not established in children
• Geri: Consider age-related ↓ in renal function.

CV: MYOCARDIAL INFARCTION, syncope.

Derm: STEVENS-JOHNSON SYNDROME (SJS), flushing, hyperhidrosis, acne, dermatitis, dry skin.

EENT: blurred vision, visual disturbances.

GI: diarrhea, gingivitis, nausea, ↑ appetite, constipation, dyspepsia, dysphagia, enterocolitis, eructation, flatulence, gallbladder disorder, GI bleeding, ↑ liver enzymes, vomiting.

Hemat: anemia.

MS: arthralgia, back pain, musculoskeletal pain, muscle cramps, myalgia, restless legs.

Neuro: HOMICIDAL THOUGHTS/BEHAVIOR, SEIZURES, STROKE, SUICIDAL THOUGHTS/BEHAVIOR, anxiety, ↓attention span, depression, insomnia, irritability, dizziness, restlessness, abnormal dreams, agitation, aggression, amnesia, anxiety, delusions, disorientation, dissociation, hallucinations, hostility, mania, mood changes, migraine, panic, paranoia, psychosis, sleepwalking.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA), accidental injury, chills, fever, mild physical dependence.

Drug-Drug:

• Smoking cessation may ↓ metabolism of theophylline, warfarin, and insulin resulting in ↑ effects; careful monitoring is recommended.
• Risk of adverse reactions (nausea, vomiting, dizziness, fatigue, headache) may be ↑ with nicotine replacement therapy (nicotine transdermal patches).
• Concomitant use with alcohol may ↑ risk of worsening neuropsychiatric events

• PO (Adults): Treatment is started one wk prior to planned smoking cessation (may also begin dosing and then quit smoking between days 8 and 35 of treatment); 0.5 mg once daily on the first three days, then 0.5 mg twice daily for the next 4 days, then 1 mg twice daily.

(Generic available)

• Tablets: 0.5 mg; 1 mg;
  • Cost: All strengths; $237.71/56.

• Assess for desire to stop smoking.
• Assess for nausea. Usually dose-dependent. May require dose reduction.
• Assess mental status and mood changes, especially during initial few mo of therapy and during dose changes. Risk may be increased in children, adolescents, and adults 24 yr. Inform health care professional if patient demonstrates significant increase in signs of depression (depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, suicide attempt or suicidal or homicidal ideation). Restrict amount of drug available to patient.
• Assess for rash periodically during therapy. May cause SJS. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.

• May cause anemia.

• PO: Administer after eating with a full glass of water.

• Instruct patient to take varenicline as directed. Set a date to stop smoking. Start taking varenicline 1 wk before quit date. Patient may also begin varenicline and then quit smoking between days 8 and 35 of therapy. Begin with 0.5 mg/day for the first 3 days, then for the next 4 days take one 0.5 mg tablet in the morning and in the evening. After first 7 days, increase to 1 mg tablet in the morning and evening. Advise patient to read Medication Guide before starting therapy.
• Encourage patient to attempt to quit, even if they had early lapses after quit day.
• Advise patient to stop taking varenicline and contact health care professional promptly if agitation, depressed mood, any changes in behavior that are not typical of nicotine withdrawal, or if suicidal thoughts or behavior; rash with mucosal lesions or skin reaction, or chest pain, pressure, or dyspnea occur. Encourage patient to reduce amount of alcohol consumed until effects of medication are known.
• Provide patient with educational materials and counseling to support attempts to quit smoking.
• Caution patient not to share varenicline with others. May be harmful.
• May cause blurred vision, dizziness, and disturbance in attention. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
• Inform patient that nausea, insomnia, and vivid, unusual, or strange dreams may occur and are usually transient. Advise patient to notify health care professional if these symptoms are persistent and bothersome; dose reduction may be considered.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications. Inform patient that some medications may require dose adjustments after quitting smoking.
• Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Monitor breastfed infants for seizures and excessive vomiting.

• Smoking cessation. Patients who have successfully stopped smoking at the end of 12 wk, should take an additional 12 wk course to increase the likelihood of long-term abstinence. Patients who do not succeed in stopping smoking during 12 wk of initial therapy or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed.

Chantix

Champix

NDC Code^*

• 0069- Pfizer Laboratories Div Pfizer Inc
  • 0069-0468- CHANTIX
    • 0069-0468-56- 56 TABLET, FILM COATED in 1 BOTTLE (0069-0468-56)

• 0069- Pfizer Laboratories Div Pfizer Inc
  • 0069-0469- CHANTIX
    • 0069-0469-03- 1 BLISTER PACK in 1 CARTON (0069-0469-03) > 56 TABLET, FILM COATED in 1 BLISTER PACK

• 0069- Pfizer Laboratories Div Pfizer Inc
  • 0069-0469- CHANTIX
    • 0069-0469-56- 56 TABLET, FILM COATED in 1 BOTTLE (0069-0469-56)

• 0069- Pfizer Laboratories Div Pfizer Inc
  • 0069-0471- CHANTIX
    • 0069-0471-03- 1 KIT in 1 CARTON (0069-0471-03) * 11 TABLET, FILM COATED in 1 BLISTER PACK * 42 TABLET, FILM COATED in 1 BLISTER PACK

• 43353- Aphena Pharma Solutions - Tennessee, LLC
  • 43353-899- CHANTIX
    • 43353-899-05- 4200 TABLET, FILM COATED in 1 BOTTLE (43353-899-05)

• 50090- A-S Medication Solutions
  • 50090-0995- CHANTIX
    • 50090-0995-0- 1 TABLET, FILM COATED in 1 KIT (50090-0995-0)

• 50090- A-S Medication Solutions
  • 50090-3528- CHANTIX
    • 50090-3528-0- 1 TABLET, FILM COATED in 1 KIT (50090-3528-0)

• 50090- A-S Medication Solutions
  • 50090-4481- CHANTIX
    • 50090-4481-0- 56 TABLET, FILM COATED in 1 BOTTLE (50090-4481-0)

• 63187- Proficient Rx LP
  • 63187-618- CHANTIX
    • 63187-618-53- 1 KIT in 1 CARTON (63187-618-53) * 11 TABLET, FILM COATED in 1 BLISTER PACK * 42 TABLET, FILM COATED in 1 BLISTER PACK

• 63539- U.S. Pharmaceuticals
  • 63539-473- CHANTIX
    • 63539-473-10- 1 KIT in 1 CARTON (63539-473-10) * 11 TABLET, FILM COATED in 1 BLISTER PACK * 14 TABLET, FILM COATED in 1 BLISTER PACK